The United Kingdom and the United States have agreed to a significant commercial pact that will keep no levies on British medicine shipments going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to boost funding on pharmaceuticals through the public health system. This move ensures that tariffs on these vital exports will stay at zero for a period of 36 months.
This development follows recent warnings to hike duties on branded drug imports, with figures floated as high as 100%.
"This deal between the UK bolsters the worldwide climate for innovative medicines and brings much-needed equity to U.S.–U.K. drug exports," a statement noted.
Commercial Importance
Pharmaceuticals are one of the UK's largest export categories to the US, which is easily the biggest market for major British pharmaceutical firms.
Trade data show that in the one-year period prior to September, the UK shipped medicines totaling billions to the US. This value accounted for nearly one-fifth of British export trade in that timeframe.
"This agreement protects employment, increases funding and facilitates the UK to become a international leader for medical research," a government official commented.
Specific British Pledges
The agreement includes several key changes from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be capped at 15%. Previously, repayments topped 20%.
Broader Context
This agreement comes amid a long-running dispute between the drug companies and the ministers over medicine costs and approval rates.
These tensions were exacerbated by assertions that American consumers were paying a premium for the identical medicines than consumers in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward US facilities.
A senior figure stated that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the last ten years.
